Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits

The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to prolonging the half-life of and reducing the risk of formation of alloantibodies (inhibitors) against FVIII in treated patients with hemophilia A (HA). The Italian health...

Full description

Bibliographic Details
Main Authors:	Mario Schiavoni, Mariasanta Napolitano, Gaetano Giuffrida, Antonella Coluccia, Sergio Siragusa, Valeria Calafiore, Giuseppe Lassandro, Paola Giordano
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-12-01
Series:	Frontiers in Medicine
Subjects:	Hemophilia A recombinant Factor VIII products pharmacokinetics inhibitors EHL-rFVIII
Online Access:	https://www.frontiersin.org/article/10.3389/fmed.2019.00261/full

Similar Items

Managing Relevant Clinical Conditions of Hemophilia A/B Patients
by: Massimo Morfini, et al.
Published: (2023-06-01)

Growing weapons to fight hemophilia
by: Pier Mannuccio Mannucci
Published: (2023-02-01)

Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
by: Chia-Yau Chang, et al.
Published: (2023-03-01)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
by: Chowdary P, et al.
Published: (2016-09-01)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
by: Zhenping Chen, et al.
Published: (2021-03-01)

Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice
by: Tischer B, et al.
Published: (2018-03-01)

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A
by: Muhammad Elnaggar, et al.
Published: (2020-06-01)

Factor VIII-Intron 1 Inversion of Hemophilia A Patients In West Anatolia
by: Pehlivan M, et al.
Published: (2007-04-01)

Repression of factor VIII inhibitor development with apoptotic factor VIII-expressing embryonic stem cells
by: Yoshihiko Sakurai, et al.
Published: (2013-07-01)

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII
by: Jenni Firrman, et al.
Published: (2020-06-01)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
by: Claude Négrier, et al.
Published: (2022-05-01)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
by: Pratima Chowdary, et al.
Published: (2019-07-01)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
by: Zhen-Ping Chen, et al.
Published: (2018-01-01)

Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A
by: Amanda M. Actor, et al.
Published: (2014-04-01)

Molecular Characterization of Hemophilia a in Southeast Bulgaria
by: Sukarova Stefanovska E, et al.
Published: (2008-01-01)

Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
by: Kun Huang, et al.
Published: (2022-02-01)

Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience
by: Giancarlo Castaman, et al.
Published: (2023-03-01)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
by: Hassan Abolghasemi, MD, et al.
Published: (2018-06-01)

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review
by: Carola Sella, et al.
Published: (2023-07-01)

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects
by: Raimondo De Cristofaro, et al.
Published: (2019-04-01)

Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement
by: Margareth Castro Ozelo, et al.
Published: (2024-01-01)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
by: Jerome Teitel, et al.
Published: (2021-02-01)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
by: Wynn TT, et al.
Published: (2016-06-01)

[Kovaltry® for the replacement therapy in patients with Hemophilia A]
by: Daniela Paola Roggeri, et al.
Published: (2016-06-01)

[Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]
by: Lucia Sara D'Angiolella, et al.
Published: (2017-02-01)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
by: Saima Bashar, et al.
Published: (2023-04-01)

Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A
by: Hemophilia Treatment Center Collaborative Network of China
Published: (2022-10-01)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
by: Yesim Dargaud, et al.
Published: (2021-12-01)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
by: Volkan Karakuş, et al.
Published: (2012-05-01)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
by: Alanna McEneny-King, et al.
Published: (2017-10-01)

Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis
by: Chonlatis Srichumpuang, et al.
Published: (2024-03-01)

Association of HLA class II Alleles and the Occurrence of Factor VIII Inhibitor in Thai Patients with Hemophilia A
by: Oytip Nathalang, et al.
Published: (2012-03-01)

Intracranial Hemorrhage in Patients With Hemophilia A
by: Nugroho Setia Budi, et al.
Published: (2020-07-01)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
by: Linari S, et al.
Published: (2020-05-01)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
by: Pocoski J, et al.
Published: (2016-07-01)

In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment
by: Yung-Tsung Kao, et al.
Published: (2023-11-01)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
by: Tine M.H.J. Goedhart, et al.
Published: (2022-01-01)

Expert opinion paper on the treatment of hemophilia A with emicizumab
by: Francisco-José López-Jaime, et al.
Published: (2023-12-01)

Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa
by: Matteo Nicola Dario Di Minno, et al.
Published: (2020-04-01)

Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A
by: Tomasz Urasiński, et al.
Published: (2023-02-01)